{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6"],"submitter":["Jiang SY"],"pubmed_abstract":["<h4>Introduction</h4>Shrimp is a common but understudied food allergen with relatively high rates of emergency department visits. Here we report the shrimp OIT outcomes in the MOTIF (NCT03504774) clinical trial and discuss some of the challenges with performing this study.<h4>Methods</h4>In this phase 2 clinical trial, 12 shrimp allergic participants aged 7-55 years (median age 21.5 years) were enrolled to receive shrimp OIT. Shrimp OIT was performed up to a maintenance dose of 1,000 mg shrimp protein by week 28 with desensitization to shrimp assessed by double-blind placebo-controlled food challenge at week 52 followed by switching to avoidance and assessing sustained unresponsiveness (SU) at week 58. The primary endpoint was the change in CD28 in CD4+ allergen specific (CD154+) T-cells a"],"journal":["Frontiers in allergy"],"pagination":["1458131"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12321884"],"repository":["biostudies-literature"],"pubmed_title":["Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF."],"pmcid":["PMC12321884"],"pubmed_authors":["Raeber O","Jiang SY","Gupta S","Sharma R","Kaushik A","Woch M","Sindher SB","Long AJ","Bogetic D","Nadeau KC","Martinez K","Maeker HT","Fernandes A","Chin AR","Manohar M","Cao S","Chinthrajah RS","Feight C"],"additional_accession":[]},"is_claimable":false,"name":"Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF.","description":"<h4>Introduction</h4>Shrimp is a common but understudied food allergen with relatively high rates of emergency department visits. Here we report the shrimp OIT outcomes in the MOTIF (NCT03504774) clinical trial and discuss some of the challenges with performing this study.<h4>Methods</h4>In this phase 2 clinical trial, 12 shrimp allergic participants aged 7-55 years (median age 21.5 years) were enrolled to receive shrimp OIT. Shrimp OIT was performed up to a maintenance dose of 1,000 mg shrimp protein by week 28 with desensitization to shrimp assessed by double-blind placebo-controlled food challenge at week 52 followed by switching to avoidance and assessing sustained unresponsiveness (SU) at week 58. The primary endpoint was the change in CD28 in CD4+ allergen specific (CD154+) T-cells a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-03-31T11:44:31.332Z","creation":"2025-08-31T03:08:42.843Z"},"accession":"S-EPMC12321884","cross_references":{"pubmed":["40766832"],"doi":["10.3389/falgy.2025.1458131"]}}